Finolex Inds. (FINPIPE)

FairStock Score: 51/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Near-zero leverage with D/E of 0.04 reduces financial risk
• Strong free cash flow of ₹391 Cr despite profit decline
• Promoter holding of 52.47% aligns ownership with minority shareholders
• Piotroski F-Score of 7/9 and Altman Z-Score of 2.55 indicate financial stability
• Latest quarter net profit of ₹110 Cr on ₹898 Cr sales shows operating resilience

Concerns

• Sales growth negative at -5.57% and profit growth sharply down at -39.62%
• ROE of 7.97% and ROCE of 8.77% indicate mediocre capital efficiency
• Valuation looks rich: P/E 24.13, EV/EBITDA 36.18, and negative 43.66% margin of safety versus Graham Number of ₹128.95
• Dividend yield of only 1.08% offers little income support while waiting for recovery

AI Analysis

I cannot ignore the first rule: protect the downside. Finolex is a nearly debt-free, family-promoted business—D/E is just 0.04, promoter holding is 52.47%, and free cash flow is ₹391 Cr. That is good. But a good balance sheet is not the same as a good business. Returns are mediocre: ROE is 7.97% and ROCE is 8.77%. The last year was painful: sales fell 5.57% and net profit fell 39.62%. A P/E of 24.13 and EV/EBITDA of 36.18 are not bargain prices; you are paying for a recovery, not for current earnings. Graham would insist on a margin of safety, and by the Graham Number, fair value is ₹128.95 against a price of ₹175.25—a negative 43.66% margin. The DCF screen shows ₹337.37, but with falling revenue and profit, a DCF is only as credible as its assumptions. Piotroski score of 7 and Altman Z-Score of 2.55 tell me the company is financially healthy and not distressed. Yet healthy companies can still be poor buys. The latest quarter had sales of ₹898 Cr and net profit of ₹110 Cr, so perhaps the decline is stabilising. But I need years of evidence, not one quarter. This is not a fast grower; it is a cyclical with temporary earnings compression. In commodity-like plastics, pricing power and returns matter. Today's returns do not justify a premium multiple. If the business can earn better returns on a cyclical upturn, it gets interesting. Until then, I would patiently stay out and wait for either a better price or demonstrated improvement.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer